Sichuan Kelun-Biotech Reports Interim Loss Amidst Key Drug Approvals

An announcement from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) is now available.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced its interim results for the first half of 2025, revealing a significant decrease in revenue and a shift from profit to loss compared to the same period in 2024. Despite the financial downturn, the company has achieved notable progress in its ADC and novel drug candidate pipeline, including receiving marketing authorization in China for sac-TMT for specific cancer treatments, marking a significant milestone as the first domestically developed ADC with global intellectual property rights to receive full marketing authorization in the country.

The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates in the biopharmaceutical industry, focusing on the development and commercialization of antibody-drug conjugates (ADCs) and novel drug candidates. The company is particularly active in advancing treatments for cancer, with a market focus on innovative therapies for conditions such as triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).

Average Trading Volume: 853,330

Technical Sentiment Signal: Buy

Current Market Cap: HK$101.2B

For an in-depth examination of 6990 stock, go to TipRanks’ Overview page.